AFFILIATIONS
1 IMRB INSERM EFS, Team Bartolucci, Créteil, France, Inserm, Centre d’Investigation Clinique 1430, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
2 IMRB INSERM EFS, Team Bartolucci, Créteil, France, Inserm, Centre d’Investigation Clinique 1430, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
3 IMRB INSERM EFS, Team Bartolucci, Créteil, France, Inserm, Centre d’Investigation Clinique 1430, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
4 IMRB INSERM EFS, Team Bartolucci, Créteil, France, Inserm, Centre d’Investigation Clinique 1430, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
5 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France
6 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France
7 Laboratoire de Pharmacologie, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Université Paris Est-Créteil, Créteil, France
8 Laboratoire de Pharmacologie, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Université Paris Est-Créteil, Créteil, France
9 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France
10 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
11 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
12 Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France
13 IMRB INSERM EFS, Team Bartolucci, Créteil, France, Inserm, Centre d’Investigation Clinique 1430, Créteil, France, Member of the ERN Eurobloodnet, Créteil, France, Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, – UMGGR, Créteil, France, Réseau Erythrocyte Drépanocytose RED, Créteil, France
ABSTRACT
Background. Despite hydroxyurea (HU) therapy, a substantial proportion of adults with sickle cell disease (SCD) remain affected by recurrent vaso-occlusive complications, reflecting heterogeneous treatment response beyond conventional biomarkers.
Methods. We conducted a prospective, single-center, pre–post implementation adult registry evaluating a structured day-hospital precision medicine optimization pathway. Eligible patients were SCD adults with HbSS, Sβ°- or Sβ?-thalassemia, or SC disease, receiving HU with a refractory vaso-occlusive profile, defined by at least one hospitalization lasting >24 hours for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) in the 12 months prior to inclusion refractory; and/or ambulatory vaso-occlusive phenotype.
At baseline, patients underwent a multidisciplinary evaluation including HU pharmacokinetic profiling (AUC) as previously reported, and psychological and adherence assessment. Each case was discussed after inclusion in a multidisciplinary board to define an individualized strategy including optimization of HU dosing (dose escalation, dose reduction, or dose maintenance) as clinically appropriate. Additional disease-modifying therapies when available (L-glutamine, crizanlizumab, or voxelotor), supportive care measures—including therapeutic education and psychological, addiction support—and referral to clinical trials or curative strategies were considered on an individualized basis. Follow-up included a structured therapeutic education visit at month 3 and clinical and biological reassessment at 6 months.
The primary endpoint was the change in annual hospitalized VOC and/or ACS events during the 12 months following pathway implementation compared with the preceding year. A “high” vaso-occlusive burden was defined as ≥2 hospitalized VOC and/or ACS events in the preceding 12 months, a threshold chosen based on population-level data showing a markedly increased mortality risk associated with recurrent hospitalized vaso-occlusive crises.
Results. Between February 2021 and February 2025, 78 adult SCD patients were enrolled (median age 28.7 years [IQR 22.7–33.6], 49% female). At baseline, patients were receiving a median dose HU of 22 mg/kg [IQR 17.5–26.0]) yet exhibited a high disease burden, with a mean of 2.99 VOC and 0.86 ACS events in the preceding year.
Overall, 48 of 78 patients (62%) experienced a reduction in annual hospitalized VOC and/or ACS events following optimization (improved patients). Median combined events per patient decreased from 3 [IQR 2–5] to 1 [IQR 0–4] (Wilcoxon signed-rank test, p = 0.0036).
Psychological assessment at baseline identified frequent HU non-adherence (62%), supported by a consistent biological profile. Changes in HU dosing, initiation of transfusion programs or add-on disease-modifying agents, and supportive care interventions did not differ between improved and non-improved patients. HU adherence was similar between groups and was not associated with clinical response.
Patients with a high baseline vaso-occlusive burden exhibited significantly higher improvement rates compared with patients with lower burden (71.7% vs 27.8%, p=0.0017). In contrast, patients who did not improve displayed higher markers of hemolysis and inflammation at baseline, including elevated reticulocyte counts, total bilirubin and leukocyte counts. Importantly, HU exposure including AUC, HbF levels, MCV, and MCH, did not differ significantly between improved and non-improved patients either at baseline or during follow-up.
Longitudinal analyses of the entire cohort showed biological changes consistent with optimized HU therapy, including increases in HbF, MCV, and MCH. Despite these shared biological improvements, longitudinal trajectories differed between groups, with a greater decline in HbS levels among improved patients and persistently higher CRP levels among non-improved patients. In multivariable analysis at baseline, high vaso-occlusive burden was independently associated with clinical improvement at 12 months (adjusted OR 6.65, 95% CI 1.69–26.27; p=0.007).
Conclusions. These findings support a phenotype-guided approach to care optimization, in which patients with high vaso-occlusive activity derive the greatest benefit from multidimensional interventions, while those with sustained hemolytic and inflammatory drive may require alternative or additional targeted strategies.